Our approach

We are shaping Parkinson’s research by delivering pre-clinical science and clinical trials that have the potential to provide drugs and other treatments that slow, stop or reverse Parkinson’s.

Much of our drive is focused on the repurposing of existing drugs, the acceleration of new pharmacological agents, and the development of regenerative therapies. Through our leading International Linked Clinical Trials (iLCT) programme, we are screening and prioritising therapies to be clinically tested, in order to bring new treatments to the clinic as soon as possible for the Parkinson’s community. Once a drug is selected, we work with an international network of hospitals to set up and conduct clinical trials.

Preclinically, our independent research committee only considers research that is within five years of clinical testing. The research committee interrogates new proposals and analyses research reports from the trials we are funding to ensure that the science is robust, progress effective and results disseminated rapidly. We encourage collaboration between scientists, scientists and patients, and funders and foster these relationships to accelerate progress and ultimately benefit people living with Parkinson’s.